News
2026
FDA Approves NEREUS: First New Motion Sickness Drug in Decades
·502 words·3 mins
FDA Approval
Pharmaceuticals
Motion Sickness
Neuropharmacology
2025
AI Unlocks New Frontiers in RNA Drug Design
·617 words·3 mins
Biotechnology
Artificial Intelligence
Drug Development
RNA Therapeutics
Targeting CSE Enzyme Opens New Paths for Alzheimer’s Treatment
·606 words·3 mins
Neuroscience
Alzheimer’s Disease
Medical Research
Brain Health
Why Alzheimer’s Trials Must Address Sex Differences
·463 words·3 mins
Medical Research
Alzheimer’s
Clinical Trials
Precision Medicine
J&J Acquires Halda Therapeutics for $3.05B
·369 words·2 mins
Biopharma
Oncology
M&A
Drug Discovery
Sanofi’s AlphaMedix Hits Key Efficacy Goals in Phase 2 Neuroendocrine Tumor Trial
·625 words·3 mins
Sanofi
AlphaMedix
Radioligand Therapy
Neuroendocrine Tumors
Oncology
Biotech
Clinical Trials
Ozempic and Cancer: Exploring GLP-1 Drugs’ Potential in Oncology
·603 words·3 mins
Ozempic
GLP-1
Cancer Research
Oncology
Weight Loss Drugs
Diabetes Drugs
How AI and Data are Shaping the Future of Inclusive Clinical Trials
·1108 words·6 mins
AI in Healthcare
Clinical Trials
Diversity in Clinical Trials
Patient Recruitment
Multiply Labs Biomanufacturing Robot Set to Slash Cell Therapy Costs
·464 words·3 mins
Cell Therapy
Gene Therapy
Biomanufacturing
Automation
Robotics
Multiply Labs
CGT
Healthcare Innovation
New Drug Candidate STF-1623 Activates Innate Immunity in Solid Tumors
·594 words·3 mins
Cancer Immunotherapy
Innate Immunity
STF-1623
ENPP1
Solid Tumors
Stanford
Lingyin Li